Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sparsentan in Posttransplant IgAN or FSGS (SPARX)
NCT07219121Phase 4Active, not recruiting
- Sponsor
- Travere Therapeutics
- Start
- Oct 2025
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
A Phase 4 trial of sparsentan in immunoglobulin A nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), sponsored by Travere Therapeutics. Started Oct 2025; status: active, not recruiting.
02
Drugs
sparsentan
03
Conditions
immunoglobulin A nephropathy (IgAN)focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT07219121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07219121.